BASILEA SEES POSITIVE RESULTS FOR CEFTOBIPROLE

Basilea Pharmaceutica has reported that its broad-spectrum antibacterial drug Ceftobiprole showed a high cure rate in patients with severe skin infections caused by bacterias.

In a Phase-III trial, the company compared the drug against Vancomycin, an antibiotic that fights bacterial infections which have proved resistant to normal antibiotics, such as hospital infections caused by staphylococci bacteria. Vancomycin was launched around 40 years ago and increasingly more bacteria have become resistant to it. The study showed that the response rate in patients treated with Ceftobiprole was higher than in patients treated with Vancomycin.